PTHS · Pelthos Therapeutics Inc. · Financials
The latest filing states the doubt was alleviated.
“in prior periods, management disclosed substantial doubt about the Company's ability to continue as a going concern. The conditions and events that previously raised substantial doubt have been alleviated by management's plans and actions.”View the 10-Q filed May 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $43.3M | $16.8M | $0 | — | — | |
| $9.27M | $3.99M | $0 | — | — | |
| $34.03M | $12.81M | $0 | — | — | |
| — | 76.25% | — | — | — | |
| $1.31M | $1.23M | $1.18M | $2.58M | $391.73K | |
| $4.31M | — | $4.11M | $2.74M | $1.1M | |
| $86.87M | $42.45M | $6.39M | — | — | |
| $3.63M | $1.56M | $0 | — | — | |
| $29.66M | — | $7.57M | $6.86M | $2.32M | |
| — | $49.23M | $7.57M | — | — | |
| -$57.78M | -$32.43M | -$7.57M | -$6.86M | -$2.32M | |
| — | -193.09% | — | — | — | |
| $7.4M | $3.01M | $786K | — | — | |
| -$36M | -$18.28M | -$384K | -$518.51K | -$140.43K | |
| -$93.78M | -$50.71M | -$7.96M | -$7.38M | -$2.46M | |
| -$7.39M | -$7.39M | $0 | — | — | |
| -$86.39M | -$43.32M | -$7.96M | -$7.38M | -$2.46M | |
| — | -257.93% | — | — | — | |
| — | -$43.32M | -$7.96M | — | — | |
| USD/shares | -$28.73 | -$23.04 | -$14.27 | -$57.80 | $56.50 |
| USD/shares | -$28.73 | -$23.04 | -$14.27 | -$57.80 | — |
| shares | — | 1.88M | 557.45K | 127.65K | 43.53K |
| shares | — | 1.88M | 557.45K | 127.65K | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $75K in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 306 similar-size Biotechnology companies (of 532 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Commercial Operations Segment | $16,206,000 | $0 |
| Research and Development Operations Segment | $589,000 | $0 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Product | $42,291,000 | — | — |
| License and Collaboration | — | $589,000 | $0 |
| Net Product | — | $16,206,000 | $0 |